Table 2.
Observed versus expected events among people vaccinated against SARS-CoV-2 or with a diagnosis of COVID-19
| N | Person-years | Observed events | Expected events | Standardised incidence ratio (95% CI) | |
|---|---|---|---|---|---|
| Deep vein thrombosis | |||||
| ChAdOx1 first-dose | 590,599 | 33,928 | 39 | 43.9 | 0.89 (0.65–1.22) |
| BNT162b2 first-dose | 2,017,986 | 100,380 | 182 | 176.4 | 1.03 (0.89–1.19) |
| BNT162b2 second-dose | 1,324,426 | 78,253 | 130 | 162.6 | 0.80 (0.67–0.95) |
| COVID-19 case | 174,081 | 40,201 | 199 | 42.5 | 4.68 (4.07–5.38) |
| Pulmonary embolism | |||||
| ChAdOx1 first-dose | 590,761 | 33,938 | 24 | 30.7 | 0.78 (0.52–1.16) |
| BNT162b2 first-dose | 2,018,466 | 100,406 | 154 | 123.2 | 1.25 (1.07–1.46) |
| BNT162b2 second-dose | 1,324,890 | 78,280 | 116 | 115.8 | 1.00 (0.84–1.20) |
| COVID-19 case | 173,905 | 40,110 | 500 | 28 | 17.86 (16.37–19.50) |
| Splanchnic vein thrombosis | |||||
| ChAdOx1 first-dose | 591,119 | 33,959 | 8 | 7.3 | 1.09 (0.54–2.18) |
| BNT162b2 first-dose | 2,020,842 | 100,542 | 14 | 18.4 | 0.76 (0.45–1.29) |
| BNT162b2 second-dose | 1,326,894 | 78,401 | 9 | 16.7 | 0.54 (0.28–1.04) |
| COVID-19 case | 174,421 | 40,298 | 13 | 4.9 | 2.64 (1.53–4.55) |
| Venous thromboembolism (deep vein thrombosis or pulmonary embolism) | |||||
| ChAdOx1 first-dose | 590,307 | 33,911 | 60 | 65.5 | 0.92 (0.71–1.18) |
| BNT162b2 first-dose | 2,015,999 | 100,266 | 313 | 264.6 | 1.18 (1.06–1.32) |
| BNT162b2 second-dose | 1,322,747 | 78,151 | 227 | 246.1 | 0.92 (0.81–1.05) |
| COVID-19 case | 173,608 | 40,031 | 630 | 61.8 | 10.19 (9.43–11.02) |
| Myocardial infarction | |||||
| ChAdOx1 first-dose | 590,016 | 33,894 | 72 | 76.1 | 0.95 (0.75–1.19) |
| BNT162b2 first-dose | 2,016,950 | 100,320 | 280 | 267.3 | 1.05 (0.93–1.18) |
| BNT162b2 second-dose | 1,323,543 | 78,197 | 272 | 247.3 | 1.10 (0.98–1.24) |
| COVID-19 case | 173,975 | 40,191 | 118 | 63.7 | 1.85 (1.55–2.22) |
| Ischaemic stroke | |||||
| ChAdOx1 first-dose | 589,870 | 33,884 | 106 | 95.6 | 1.11 (0.92–1.34) |
| BNT162b2 first-dose | 2,012,434 | 100,055 | 521 | 530.5 | 0.98 (0.90–1.07) |
| BNT162b2 second-dose | 1,319,429 | 77,948 | 515 | 510.9 | 1.01 (0.92–1.10) |
| COVID-19 case | 173,390 | 39,983 | 577 | 106.5 | 5.42 (5.00–5.88) |
| Arterial thromboembolism (myocardial infarction or ischaemic stroke) | |||||
| ChAdOx1 first-dose | 588,689 | 33,815 | 178 | 168.2 | 1.06 (0.91–1.23) |
| BNT162b2 first-dose | 2,008,196 | 99,814 | 793 | 780.7 | 1.02 (0.95–1.09) |
| BNT162b2 second-dose | 1,315,777 | 77,726 | 774 | 741.9 | 1.04 (0.97–1.12) |
| COVID-19 case | 172,905 | 39,868 | 683 | 165.4 | 4.13 (3.83–4.45) |
| Immune thrombocytopenia | |||||
| ChAdOx1 first-dose | 590,919 | 33,947 | 12 | 24.9 | 0.48 (0.27–0.85) |
| BNT162b2 first-dose | 2,019,395 | 100,459 | 97 | 94.3 | 1.03 (0.84–1.26) |
| BNT162b2 second-dose | 1,325,627 | 78,325 | 61 | 89 | 0.69 (0.53–0.88) |
| COVID-19 case | 174,145 | 40,188 | 292 | 22 | 13.29 (11.85–14.91) |
| Thrombocytopenia | |||||
| ChAdOx1 first-dose | 577,534 | 33,156 | 754 | 588.5 | 1.28 (1.19–1.38) |
| BNT162b2 first-dose | 1,952,174 | 96,641 | 3186 | 2145.40 | 1.49 (1.43–1.54) |
| BNT162b2 second-dose | 1,264,798 | 74,678 | 2749 | 1963.20 | 1.40 (1.35–1.45) |
| COVID-19 case | 167,218 | 38,379 | 2476 | 539.9 | 4.59 (4.41–4.77) |
| Deep vein thrombosis with thrombocytopenia | |||||
| BNT162b2 first-dose | 2,020,823 | 100,541 | 12 | 12.8 | 0.94 (0.53–1.65) |
| BNT162b2 second-dose | 1,326,869 | 78,400 | 7 | 12 | 0.58 (0.28–1.22) |
| COVID-19 case | 174,409 | 40,295 | 25 | 3 | 8.32 (5.62–12.32) |
| Pulmonary embolism with thrombocytopenia | |||||
| BNT162b2 first-dose | 2,020,780 | 100,538 | 21 | 12.4 | 1.70 (1.11–2.61) |
| BNT162b2 second-dose | 1,326,837 | 78,398 | 15 | 11.7 | 1.29 (0.78–2.13) |
| COVID-19 case | 174,370 | 40,280 | 61 | 2.9 | 21.37 (16.63–27.46) |
| Venous thromboembolism (deep vein thrombosis or pulmonary embolism) with thrombocytopenia | |||||
| ChAdOx1 first-dose | 591,096 | 33,957 | 8 | 6.3 | 1.28 (0.64–2.56) |
| BNT162b2 first-dose | 2,020,650 | 100,531 | 27 | 21.7 | 1.24 (0.85–1.82) |
| BNT162b2 second-dose | 1,326,723 | 78,391 | 20 | 20.4 | 0.98 (0.63–1.52) |
| COVID-19 case | 174,337 | 40,272 | 78 | 5 | 15.48 (12.40–19.32) |
| Arterial thromboembolism (myocardial infarction or ischaemic stroke) with thrombocytopenia | |||||
| ChAdOx1 first-dose | 591,014 | 33,952 | 9 | 11.7 | 0.77 (0.40–1.48) |
| BNT162b2 first-dose | 2,020,074 | 100,497 | 53 | 62 | 0.86 (0.65–1.12) |
| BNT162b2 second-dose | 1,326,182 | 78,358 | 59 | 59.8 | 0.99 (0.76–1.27) |
| COVID-19 case | 174,297 | 40,269 | 58 | 12.6 | 4.62 (3.57–5.98) |
For each event of interest, the number of people contributing to the analysis from the target population, their person-years contributed, and the number of observed events are given. Expected events are estimated using indirect standardisation to the general population. Standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) were estimated. Events with fewer than 5 occurrences were omitted to protect patient confidentiality.